Harrow (NASDAQ:HROW – Get Free Report) and Clene (NASDAQ:CLNN – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
Volatility & Risk
Harrow has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Harrow and Clene, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Harrow | 1 | 2 | 7 | 0 | 2.60 |
| Clene | 1 | 0 | 6 | 0 | 2.71 |
Earnings & Valuation
This table compares Harrow and Clene”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Harrow | $272.30 million | 4.20 | -$5.14 million | ($1.00) | -30.48 |
| Clene | $200,000.00 | 265.00 | -$26.17 million | ($3.50) | -1.17 |
Harrow has higher revenue and earnings than Clene. Harrow is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Harrow and Clene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Harrow | -13.51% | -38.00% | -3.37% |
| Clene | -20,063.96% | N/A | -137.04% |
Insider and Institutional Ownership
72.8% of Harrow shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 12.8% of Harrow shares are held by insiders. Comparatively, 28.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
About Harrow
Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.
About Clene
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
